NCT00741585

Brief Summary

The HYGIA study was designed to investigate prospectively

  1. 1.the prognostic value of ambulatory blood pressure (BP) monitoring among subjects primarily evaluated at primary care settings
  2. 2.the impact of changes in ambulatory BP during follow-up in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
  3. 3.the influence of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
  4. 4.the prevalence of an altered BP profile as a function of antihypertensive treatment, circadian time of treatment, age, and presence of diabetes, among other factors.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21,983

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Sep 2008

Longer than P75 for phase_4

Geographic Reach
1 country

20 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 26, 2008

Completed
6 days until next milestone

Study Start

First participant enrolled

September 1, 2008

Completed
9.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2018

Completed
Last Updated

August 28, 2018

Status Verified

August 1, 2018

Enrollment Period

9.8 years

First QC Date

August 25, 2008

Last Update Submit

August 24, 2018

Conditions

Keywords

Ambulatory blood pressure monitoringChronotherapyCircadianNon-dipperType 2 diabetesResistant hypertensionTotal mortality

Outcome Measures

Primary Outcomes (1)

  • To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.

    Yearly evaluation for at least ten years

Secondary Outcomes (8)

  • To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.

    Yearly evaluation for at least ten years

  • To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.

    Yearly evaluation for at least ten years

  • To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.

    Yearly evaluation for at least ten years

  • To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.

    Yearly evaluation for at least ten years

  • To evaluate, for all groups of interest, the prevalence and vascular, metabolic, and renal risk profile of white-coat hypertension.

    Yearly evaluation for at least ten years

  • +3 more secondary outcomes

Study Arms (2)

1

ACTIVE COMPARATOR

Treatment with all prescribed hypertension medications on awakening

Drug: Any antihypertensive medication alone or in combinationDevice: Ambulatory blood pressure monitoring

2

ACTIVE COMPARATOR

Treatment with at least one prescribed hypertension medication at bedtime

Drug: Any antihypertensive medication alone or in combinationDevice: Ambulatory blood pressure monitoring

Interventions

All drugs on awakening

Also known as: Olmesartan, Irbesartan, Candesartan, Telmisartan, Valsartan, Atenolol, Carvedilol, Nevibolol, Doxazosine, Lercanidipine, Manidipine, Amlodipine, Ramipril, Enalapril, Lisinopril, Quinapril
1

Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours

Also known as: ABPM
12

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female subjects ≥18 years of age.
  • High-normal BP or essential hypertension.
  • Any subject with recommendation for evaluation with ABPM according to the 2007 European Guidelines.
  • Informed consent to participate in the study prior to any study procedures.

You may not qualify if:

  • Known or suspected contraindications to any potential medication under investigation.
  • Shift-workers.
  • Inability to communicate and comply with all study requirements.
  • Persons directly involved in the execution of this protocol.
  • Intolerants to the use of the ABPM device.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (20)

CS Friol

Friol, Lugo, 27220, Spain

Location

CS A Estrada

A Estrada, Pontevedra, 26680, Spain

Location

CS Baiona

Baiona, Pontevedra, 36300, Spain

Location

CS Bueu

Bueu, Pontevedra, 36930, Spain

Location

CS A Guarda

La Guardia, Pontevedra, 36780, Spain

Location

CS Valmiñor

Nigrán, Pontevedra, 36250, Spain

Location

CS Panxón

Nigrán, Pontevedra, 36340, Spain

Location

CS Tomiño

Tomiño, Pontevedra, 36200, Spain

Location

Bioengineering & Chronobilogy Labs., University of Vigo

Vigo, Pontevedra, 36200, Spain

Location

Hospital do Meixoeiro

Vigo, Pontevedra, 36200, Spain

Location

CS Calle Cuba

Vigo, Pontevedra, 36202, Spain

Location

CS A Doblada

Vigo, Pontevedra, 36205, Spain

Location

CS Coia

Vigo, Pontevedra, 36209, Spain

Location

CS Sardoma

Vigo, Pontevedra, 36214, Spain

Location

CS Teis

Vigo, Pontevedra, 36216, Spain

Location

CS Vilaboa

Vilaboa, Pontevedra, 36141, Spain

Location

CS San Roque

Vilagarcía de Arousa, Pontevedra, 36600, Spain

Location

CS Fingoi

Lugo, 27002, Spain

Location

Complexo Hospitalario Universitario de Ourense

Ourense, 32005, Spain

Location

CS Lerez

Pontevedra, 36156, Spain

Location

Related Publications (2)

  • Hermida RC, Crespo JJ, Dominguez-Sardina M, Otero A, Moya A, Rios MT, Sineiro E, Castineira MC, Callejas PA, Pousa L, Salgado JL, Duran C, Sanchez JJ, Fernandez JR, Mojon A, Ayala DE; Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020 Dec 21;41(48):4565-4576. doi: 10.1093/eurheartj/ehz754.

  • Hermida RC. Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project. Chronobiol Int. 2016;33(7):906-36. doi: 10.1080/07420528.2016.1181078. Epub 2016 May 24.

MeSH Terms

Conditions

Essential HypertensionCardiovascular DiseasesStrokeRenal Insufficiency, ChronicDiabetes Mellitus, Type 2

Interventions

olmesartanIrbesartancandesartanTelmisartanValsartanAtenololCarvedilolDoxazosinlercanidipinemanidipineAmlodipineRamiprilEnalaprilLisinoprilQuinaprilBlood Pressure Monitoring, Ambulatory

Condition Hierarchy (Ancestors)

HypertensionVascular DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsSpiro CompoundsTetrazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPolycyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingValineAmino Acids, Branched-ChainAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, EssentialPhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsPropanolsAminesCarbazolesIndolesHeterocyclic Compounds, 3-RingPrazosinQuinazolinesDihydropyridinesPyridinesDipeptidesOligopeptidesPeptidesTetrahydroisoquinolinesIsoquinolinesBlood Pressure DeterminationDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisMonitoring, AmbulatoryMonitoring, Physiologic

Study Officials

  • Ramon C Hermida, PhD

    University of Vigo

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 25, 2008

First Posted

August 26, 2008

Study Start

September 1, 2008

Primary Completion

June 30, 2018

Study Completion

June 30, 2018

Last Updated

August 28, 2018

Record last verified: 2018-08

Locations